A recent study has shown the effectiveness of nirsevimab in reducing RSV-linked hospitalizations in infants. The findings emphasize the importance of health care planning to follow vaccination recommendations for RSV prevention. It is crucial for parents to protect their infants early in the RSV season through either maternal vaccination during pregnancy or administering nirsevimab to newborns. Infants born during the RSV season, who are not covered by maternal vaccination, should receive nirsevimab within the first week of life, ideally during their birth hospitalization. These recommendations aim to decrease the burden of RSV-related hospitalizations and ensure the health and safety of infants during the RSV season.
Read more about this — here
